Cargando…

Deoxynivalenol and Its Modified Forms: Are There Major Differences?

Considering the diverse toxic effects of the Fusarium toxin deoxynivalenol (DON), its common occurrence in wheat-based products, and its stability during processing, DON constitutes an increasing health concern for humans and animals. In addition to the parent compound DON, human and animal exposure...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizadeh, Arash, Braber, Saskia, Akbari, Peyman, Kraneveld, Aletta, Garssen, Johan, Fink-Gremmels, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127130/
https://www.ncbi.nlm.nih.gov/pubmed/27854268
http://dx.doi.org/10.3390/toxins8110334
_version_ 1782470216914042880
author Alizadeh, Arash
Braber, Saskia
Akbari, Peyman
Kraneveld, Aletta
Garssen, Johan
Fink-Gremmels, Johanna
author_facet Alizadeh, Arash
Braber, Saskia
Akbari, Peyman
Kraneveld, Aletta
Garssen, Johan
Fink-Gremmels, Johanna
author_sort Alizadeh, Arash
collection PubMed
description Considering the diverse toxic effects of the Fusarium toxin deoxynivalenol (DON), its common occurrence in wheat-based products, and its stability during processing, DON constitutes an increasing health concern for humans and animals. In addition to the parent compound DON, human and animal exposure encompasses the acetylated fungal metabolites 3-acetyl-deoxynivalenol (3ADON) and 15-acetyl-deoxynivalenol (15ADON) as well as the plant-derived DON-glucoside (DON3G) and the bacterial product de-epoxy-DON (DOM-1). In the current study we used the well-established Caco-2 cell model to compare the effects of these naturally occurring forms of DON on cell viability and markers of barrier integrity, as well as on the release of the pro-inflammatory chemokine chemokine CXC motif ligand (CXCL8). Results show that 3ADON is less potent in inducing adverse effects on barrier integrity when compared to DON, whereas 15ADON appears to be slightly more potent than DON. In contrast, DON3G and DOM-1 exerted no measurable adverse effects on the intestinal barrier. It was also demonstrated that galacto-oligosaccharides (GOS) are able to protect epithelial cells against DON and its acetylated forms, which suggests that GOS are beneficial food additives in the protection of vulnerable segments of the human population against adverse effects of DON and its derivatives.
format Online
Article
Text
id pubmed-5127130
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51271302016-12-02 Deoxynivalenol and Its Modified Forms: Are There Major Differences? Alizadeh, Arash Braber, Saskia Akbari, Peyman Kraneveld, Aletta Garssen, Johan Fink-Gremmels, Johanna Toxins (Basel) Article Considering the diverse toxic effects of the Fusarium toxin deoxynivalenol (DON), its common occurrence in wheat-based products, and its stability during processing, DON constitutes an increasing health concern for humans and animals. In addition to the parent compound DON, human and animal exposure encompasses the acetylated fungal metabolites 3-acetyl-deoxynivalenol (3ADON) and 15-acetyl-deoxynivalenol (15ADON) as well as the plant-derived DON-glucoside (DON3G) and the bacterial product de-epoxy-DON (DOM-1). In the current study we used the well-established Caco-2 cell model to compare the effects of these naturally occurring forms of DON on cell viability and markers of barrier integrity, as well as on the release of the pro-inflammatory chemokine chemokine CXC motif ligand (CXCL8). Results show that 3ADON is less potent in inducing adverse effects on barrier integrity when compared to DON, whereas 15ADON appears to be slightly more potent than DON. In contrast, DON3G and DOM-1 exerted no measurable adverse effects on the intestinal barrier. It was also demonstrated that galacto-oligosaccharides (GOS) are able to protect epithelial cells against DON and its acetylated forms, which suggests that GOS are beneficial food additives in the protection of vulnerable segments of the human population against adverse effects of DON and its derivatives. MDPI 2016-11-16 /pmc/articles/PMC5127130/ /pubmed/27854268 http://dx.doi.org/10.3390/toxins8110334 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alizadeh, Arash
Braber, Saskia
Akbari, Peyman
Kraneveld, Aletta
Garssen, Johan
Fink-Gremmels, Johanna
Deoxynivalenol and Its Modified Forms: Are There Major Differences?
title Deoxynivalenol and Its Modified Forms: Are There Major Differences?
title_full Deoxynivalenol and Its Modified Forms: Are There Major Differences?
title_fullStr Deoxynivalenol and Its Modified Forms: Are There Major Differences?
title_full_unstemmed Deoxynivalenol and Its Modified Forms: Are There Major Differences?
title_short Deoxynivalenol and Its Modified Forms: Are There Major Differences?
title_sort deoxynivalenol and its modified forms: are there major differences?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127130/
https://www.ncbi.nlm.nih.gov/pubmed/27854268
http://dx.doi.org/10.3390/toxins8110334
work_keys_str_mv AT alizadeharash deoxynivalenolanditsmodifiedformsaretheremajordifferences
AT brabersaskia deoxynivalenolanditsmodifiedformsaretheremajordifferences
AT akbaripeyman deoxynivalenolanditsmodifiedformsaretheremajordifferences
AT kraneveldaletta deoxynivalenolanditsmodifiedformsaretheremajordifferences
AT garssenjohan deoxynivalenolanditsmodifiedformsaretheremajordifferences
AT finkgremmelsjohanna deoxynivalenolanditsmodifiedformsaretheremajordifferences